ATP抗肿瘤药物敏感性检测技术与卵巢癌临床治疗的相关性研究

目的 采用三磷酸腺苷生物荧光法(ATP-TCA)对卵巢癌组织标本进行体外药敏试验,并分析其与临床疗效的相关性。方法 取卵巢癌患者术后新鲜组织和腹水标本共34例,应用ATP-TCA技术对9种10组化疗药物进行体外药敏试验。结果 ATP-TCA技术的可评价率为94．0％,敏感性为90．0％,特异性为91．7％,阳性预测值为94．7％,阴性预测值为84．6％．整体预测值为90．6％。药物体外药敏检测结果与临床资料相符率较高。结论 ATP-TCA体外药敏检测结果与临床治疗反应有很好的相关性,是开展肿瘤个体化化疗的一种重要的体外药物筛选方法。

Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer

Objective To determine the correlation between results of ATP bioluminescence tumor chemosensitivity assay (ATP-TCA) of human ovarian cancer specimens in vitro and clinical chemo-therapeutic responses of patients. Methods Thirty-four freshly taken ovarian cancer specimens (28 cases) and ascites (6 cases) and 9 chemotherapeutic drugs were tested in vitro for cancer chemosensitivity by ATP-TCA. Results Among the 34 ovarian cancer cases, the efficacy of ATP-TCA is 94.0%, the sensitivity, the specificity, the positive and negative predicting values, and an overall predicting value in vitro and vivo were 90.0%, 91.7%, ~94.7% ,~84.6% and 90.6%, respectively. Conclusion The results of ATP-TCA assay are correlated well with clinical treatment responses. The assay may be an important and useful method for individual-based chemotherapy of cancers.